
Novartis pulls fevipiprant development in asthma following trial failure
pharmafile | December 16, 2019 | News story | Research and Development, Sales and Marketing | Fevipiprant, Novartis, asthma, pharma, trial failure
Novartis has made it known that its DP2 receptor antagonist fevipiprant failed at Phase 3 to show clinically relevant levels of efficacy in the treatment of inadequately controlled moderate-to-severe asthma.
The firm announced that neither the 150mg or 450mg therapy formulations reached the “clinically relevant threshold” in reducing the moderate-to-severe exacerbation rate over 52 weeks in asthma patients who had received inhaled mid-to-high dose corticosteroids (ICS) and at least one additional controller, compared to placebo.
Novartis said that the data “do not support further development of fevipiprant in asthma”.
However, Novartis’ noted that the therapy was “generally well-tolerated”. Full efficacy and safety data was confirmed to be under analysis and will be presented at an upcoming medical meeting.
“While the results of the LUSTER studies with fevipiprant are disappointing, they meaningfully contribute to our understanding of the DP2 pathway in asthma. We are incredibly grateful to all the patients, their families and the investigators who participated in the studies and contributed greatly to this research,” remarked John Tsai, Head Global Drug Development and Chief Medical Officer at Novartis.
Matt Fellows
Related Content

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …

MHRA approves first lower-carbon beclometasone inhalers for asthma
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the world’s first pressurised metered …






